Nucleoside Metabolic Inhibitor class drugs

10 results

  • decitabine

    (Decitabine)
    Meitheal Pharmaceuticals Inc.
    Decitabine for Injection is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including various subtypes and risk groups, both previously treated and untreated, de novo and secondary MDS.
    Medication Details
    Drug Interactions

  • fluorouracil

    (Fluorouracil)
    Alembic Pharmaceuticals Inc.
    This drug is indicated for the treatment of various adenocarcinomas, specifically adenocarcinoma of the colon and rectum, breast, gastric, and pancreatic regions.
    Medication Details
    Drug Interactions

  • gemcitabine

    (GEMCITABINE)
    Fresenius Kabi USA, LLC
    Gemcitabine for Injection is indicated for advanced ovarian cancer (after platinum therapy), metastatic breast cancer (after anthracycline failure), non-small cell lung cancer (inoperable or metastatic), and pancreatic cancer (locally advanced or metastatic, following fluorouracil treatment).
    Medication Details
    Drug Interactions

  • inqovi

    (CEDAZURIDINE and DECITABINE)
    Taiho Pharmaceutical Co., Ltd.
    INQOVI is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including various subtypes and risk groups as per the International Prognostic Scoring System, applicable to both previously treated and untreated cases.
    Medication Details
    Drug Interactions

  • lonsurf

    (trifluridine and tipiracil)
    Taiho Pharmaceutical Co., Ltd.
    LONSURF is indicated for adult patients with metastatic colorectal cancer previously treated with specified chemotherapy regimens and targeted therapies, and for those with metastatic gastric or gastroesophageal junction adenocarcinoma after two prior chemotherapy lines involving fluoropyrimidine and platinum-based treatments.
    Medication Details
    Drug Interactions

  • vyxeos

    ((daunorubicin and cytarabine) liposome)
    Jazz Pharmaceuticals, Inc.
    VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients aged 1 year and older.
    Medication Details
    Drug Interactions